The global anti-vascular endothelial growth factor (VEGF) therapeutics market has witnessed substantial development in recent years, largely driven by the rising prevalence of chronic ophthalmic and oncological conditions. Valued at USD 12.09 billion in 2021, the market is expected to grow modestly, registering a compound annual growth rate (CAGR) of 0.4% during the forecast period (2022–2030), and is projected to reach USD 13.32 billion by 2030.
Anti-VEGF therapeutics are a class of biopharmaceuticals that inhibit VEGF proteins responsible for stimulating the growth of new blood vessels. These therapies are critical in managing diseases such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and various cancers. With an aging global population and rising incidences of lifestyle-related diseases, demand for effective anti-VEGF treatments remains high. However, the market is also challenged by patent expirations, high therapy costs, and competition from biosimilars.
Market Segmentation
The anti-VEGF therapeutics market can be segmented on the basis of drug type, application, distribution channel, and region.
By Drug Type
- Ranibizumab (Lucentis) – Widely prescribed for AMD and diabetic eye disease; remains one of the top contributors to market revenue.
- Aflibercept (Eylea) – A leading therapy with strong adoption due to its efficacy and relatively reduced dosing frequency.
- Bevacizumab (Avastin) – Initially developed for oncology; increasingly used off-label in ophthalmology due to cost-effectiveness.
- Brolucizumab (Beovu) – A newer generation drug offering longer-lasting effects, reducing patient treatment burden.
- Others (including biosimilars and pipeline drugs) – Emerging biosimilars are expected to challenge established players by offering affordable alternatives.
By Application
- Ophthalmology
- Age-Related Macular Degeneration (AMD)
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Oncology
- Colorectal Cancer
- Lung Cancer
- Renal Cell Carcinoma
- Others
By Distribution Channel
- Hospital Pharmacies – Major share due to institutional treatment settings.
- Retail Pharmacies – Growing accessibility to ophthalmology drugs boosts this segment.
- Online Pharmacies – Increasing adoption driven by digital health platforms and convenience.
Regional Analysis
North America
North America dominates the global anti-VEGF therapeutics market, accounting for the largest revenue share. The region benefits from advanced healthcare infrastructure, strong presence of key biopharma companies, high prevalence of AMD and diabetic retinopathy, and favorable reimbursement policies. The United States remains the leading contributor, driven by high healthcare spending and early adoption of innovative therapeutics.
Europe
Europe holds the second-largest market share, supported by increasing elderly population, well-established healthcare systems, and regulatory approvals for new therapeutics. Countries like Germany, the U.K., and France are significant markets, while Eastern Europe shows potential due to growing healthcare investments.
Asia-Pacific
The Asia-Pacific region is expected to grow at the fastest rate over the forecast period. Rapid urbanization, rising diabetes cases, expanding healthcare access, and growing awareness of eye health are fueling market growth. Countries such as China, India, and Japan are witnessing significant uptake of anti-VEGF therapies, supported by government initiatives and increased patient affordability.
Latin America
Latin America represents a steadily growing market, with Brazil and Mexico leading due to improved healthcare infrastructure and rising incidence of chronic diseases. However, high drug costs limit broader market penetration in low- and middle-income populations.
Middle East & Africa
The Middle East & Africa region is still in a nascent growth stage but is projected to show steady demand as healthcare infrastructure improves. Government initiatives to combat blindness and cancer will provide new opportunities for anti-VEGF therapeutic adoption.
Key Market Growth Drivers
- Rising Incidence of Ophthalmic Diseases
Increasing prevalence of AMD, diabetic retinopathy, and retinal vein occlusion globally is a primary factor boosting demand for anti-VEGF therapies. - Growing Geriatric Population
The risk of AMD and related eye conditions increases with age, and the expanding elderly demographic worldwide will contribute significantly to market growth. - Advancements in Drug Development
Innovations in long-acting formulations (e.g., brolucizumab) reduce dosing frequency, enhancing patient compliance and driving adoption. - Oncology Applications
Anti-VEGF agents like bevacizumab remain essential in treating cancers such as colorectal, lung, and renal cell carcinoma, broadening the therapeutic scope. - Government & NGO Initiatives
Programs aimed at reducing blindness and promoting access to advanced eye care in developing countries are accelerating treatment uptake.
Market Challenges
- High Cost of Treatment
Anti-VEGF drugs, particularly branded versions, remain expensive, limiting access in low-income countries and straining healthcare budgets. - Patent Expirations & Biosimilar Competition
Patent expirations for blockbuster drugs like Lucentis and Avastin have opened the market to biosimilars, pressuring prices and reducing revenues for originator companies. - Treatment Burden & Patient Compliance Issues
Frequent intravitreal injections create a significant treatment burden, leading to reduced adherence among patients. - Regulatory & Reimbursement Barriers
Stringent regulatory approvals and inconsistent reimbursement policies across regions hinder the timely availability of innovative drugs. - Adverse Effects
Potential side effects, including ocular inflammation and systemic risks, may limit patient acceptance and necessitate ongoing safety monitoring.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
Key Companies in the Market
- Genentech (Roche) – Producer of Avastin and Lucentis, major global players in both oncology and ophthalmology segments.
- Regeneron Pharmaceuticals – Developer of Eylea, a leading drug with strong global sales.
- Novartis AG – Key player with brolucizumab (Beovu) and partnerships for global drug distribution.
- Pfizer Inc. – Active in oncology with anti-VEGF therapeutic portfolios.
- Bayer AG – Collaborates with Regeneron in distributing Eylea outside the U.S.
- Samsung Bioepis & Amgen – Leading biosimilar developers entering the market with cost-effective alternatives.
- Others – Biocon, Alcon, and emerging biotech companies focusing on next-generation VEGF inhibitors.
Conclusion
The global anti-VEGF therapeutics market is poised for modest but steady growth over the next decade, reaching USD 13.32 billion by 2030. While the market faces challenges from patent expirations, biosimilar competition, and treatment costs, its fundamentals remain strong due to the rising burden of eye-related diseases, aging populations, and oncology applications. Companies investing in longer-acting, affordable, and safer formulations are likely to gain a competitive edge in the evolving landscape.
The future of this market will depend heavily on innovations in drug delivery, biosimilar penetration, and accessibility in emerging economies, making it an attractive yet competitive space for pharmaceutical and biotechnology companies worldwide.
More Trending Latest Reports By Polaris Market Research:
Distribution Transformer Market
Transcatheter Aortic Valve Replacement (Tavr) Market
Veterinary Artificial Insemination Market
Molecular Sieve Desiccants Market
Agriculture Silos & Storage Systems Market
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek